NASDAQ:IMVT

Immunovant Stock Insider Trading

Healthcare > Biotechnology

Buy IMVT

*Your capital is at risk

$37.62

-0.480 (-1.26%)

At Close: Jun 23, 2026

Immunovant Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 90.46. In total, the insiders bought 26.23M and sold 735.97K IMVT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	90.46
● Buy	26.23M shares
● Sell	735.97K shares
53% Buy Activity Moderate Negative Correlation
Sell Signal Low Confidence May 28, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 90.46. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Apr 08, 2026 Sell	Common Stock S-Sale	Gloria Melanie Chief Operating Officer	C-Suite Officer	8 722 Value: $216.6K
Apr 08, 2026 Sell	Common Stock S-Sale	Van Tuyl Christopher Chief Legal Officer	Officer	5 165 Value: $128.2K
Apr 07, 2026 Buy	Stock Option (right to buy) A-Award	Girao Tiago Chief Financial Officer	C-Suite Officer	94 002 Value: $2.31M
Apr 07, 2026 Buy	Common Stock A-Award	Girao Tiago Chief Financial Officer	C-Suite Officer	64 968 Value: $1.60M
Apr 07, 2026 Buy	Common Stock A-Award	Venker Eric Chief Executive Officer	CEO / President	232 252 Value: $5.72M
Apr 07, 2026 Buy	Stock Option (right to buy) A-Award	Venker Eric Chief Executive Officer	CEO / President	336 043 Value: $8.27M
Apr 07, 2026 Buy	Stock Option (right to buy) A-Award	Van Tuyl Christopher Chief Legal Officer	Officer	59 820 Value: $1.47M
Apr 07, 2026 Buy	Common Stock A-Award	Van Tuyl Christopher Chief Legal Officer	Officer	41 343 Value: $1.02M
Apr 07, 2026 Buy	Stock Option (right to buy) A-Award	Stout Jay S Chief Technology Officer	Officer	96 851 Value: $2.38M
Apr 07, 2026 Buy	Common Stock A-Award	Torti Frank Director	Director	174 189 Value: $4.29M
Apr 07, 2026 Buy	Stock Option (right to buy) A-Award	Torti Frank Director	Director	88 325 Value: $2.17M
Apr 07, 2026 Buy	Common Stock A-Award	Fromkin Andrew J. Director	Director	13 880 Value: $341.6K
Apr 07, 2026 Buy	Stock Option (right to buy) A-Award	Fromkin Andrew J. Director	Director	7 061 Value: $173.8K
Apr 07, 2026 Buy	Common Stock A-Award	Hughes Douglas J. Director	Director	13 880 Value: $341.6K
Apr 07, 2026 Buy	Stock Option (right to buy) A-Award	Hughes Douglas J. Director	Director	7 061 Value: $173.8K
Apr 07, 2026 Buy	Common Stock A-Award	Pande Atul Director	Director	13 880 Value: $341.6K
Apr 07, 2026 Buy	Stock Option (right to buy) A-Award	Pande Atul Director	Director	7 061 Value: $173.8K
Apr 07, 2026 Buy	Common Stock A-Award	Bauer Jake Director	Director	13 880 Value: $341.6K
Apr 07, 2026 Buy	Stock Option (right to buy) A-Award	Bauer Jake Director	Director	7 061 Value: $173.8K
Apr 07, 2026 Buy	Common Stock A-Award	Susman Robert Graham Director	Director	13 880 Value: $341.6K
Apr 07, 2026 Buy	Stock Option (right to buy) A-Award	Susman Robert Graham Director	Director	7 061 Value: $173.8K
Apr 07, 2026 Buy	Common Stock A-Award	Gloria Melanie Chief Operating Officer	C-Suite Officer	83 671 Value: $2.06M
Apr 07, 2026 Buy	Stock Option (right to buy) A-Award	Gloria Melanie Chief Operating Officer	C-Suite Officer	121 063 Value: $2.98M
Apr 07, 2026 Buy	Common Stock A-Award	Stout Jay S Chief Technology Officer	Officer	66 937 Value: $1.65M
Apr 02, 2026 Sell	Common Stock S-Sale	Venker Eric Chief Executive Officer	CEO / President	12 820 Value: $308.2K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT IMMUNOVANT, INC.

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for...

Read Full Profile Here